Kaichi Nishiwaki

1.2k total citations
48 papers, 587 citations indexed

About

Kaichi Nishiwaki is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Kaichi Nishiwaki has authored 48 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 19 papers in Genetics and 12 papers in Rheumatology. Recurrent topics in Kaichi Nishiwaki's work include Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Eosinophilic Disorders and Syndromes (11 papers). Kaichi Nishiwaki is often cited by papers focused on Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Eosinophilic Disorders and Syndromes (11 papers). Kaichi Nishiwaki collaborates with scholars based in Japan, United States and Australia. Kaichi Nishiwaki's co-authors include Hidekazu Masuoka, Ken Kaito, Tatsuo Hosoya, Yoji Ogasawara, Shingo Yano, Hisashi Wakita, Kazuhito Suzuki, Masayuki Kobayashi, Chiaki Nakaseko and Michiko Kobayashi and has published in prestigious journals such as Blood, Annals of Oncology and Cancer Letters.

In The Last Decade

Kaichi Nishiwaki

46 papers receiving 578 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaichi Nishiwaki Japan 12 476 227 176 127 111 48 587
Léonardo Magro France 11 270 0.6× 116 0.5× 105 0.6× 123 1.0× 119 1.1× 43 469
Yoshiko Matsuhashi Japan 12 336 0.7× 115 0.5× 117 0.7× 31 0.2× 147 1.3× 41 521
Péter Reményi Hungary 13 228 0.5× 135 0.6× 64 0.4× 44 0.3× 89 0.8× 44 400
C. Costello United Kingdom 12 196 0.4× 209 0.9× 130 0.7× 64 0.5× 80 0.7× 19 510
Monica Soracco Italy 13 476 1.0× 157 0.7× 160 0.9× 61 0.5× 213 1.9× 24 640
Chiara Maria Dellacasa Italy 15 457 1.0× 417 1.8× 55 0.3× 163 1.3× 120 1.1× 37 752
Rainer Krahl Germany 14 754 1.6× 350 1.5× 44 0.3× 131 1.0× 106 1.0× 42 868
AH Elmaagacli Germany 13 413 0.9× 156 0.7× 66 0.4× 69 0.5× 95 0.9× 15 531
Toshiro Kawakita Japan 11 319 0.7× 91 0.4× 105 0.6× 28 0.2× 75 0.7× 77 504
Woo‐Sung Min South Korea 14 323 0.7× 119 0.5× 61 0.3× 26 0.2× 104 0.9× 34 451

Countries citing papers authored by Kaichi Nishiwaki

Since Specialization
Citations

This map shows the geographic impact of Kaichi Nishiwaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaichi Nishiwaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaichi Nishiwaki more than expected).

Fields of papers citing papers by Kaichi Nishiwaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaichi Nishiwaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaichi Nishiwaki. The network helps show where Kaichi Nishiwaki may publish in the future.

Co-authorship network of co-authors of Kaichi Nishiwaki

This figure shows the co-authorship network connecting the top 25 collaborators of Kaichi Nishiwaki. A scholar is included among the top collaborators of Kaichi Nishiwaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaichi Nishiwaki. Kaichi Nishiwaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Suzuki, Kazuhito, Yutaka Shimazu, Takashi Ikeda, et al.. (2023). Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis. Transplantation and Cellular Therapy. 29(11). 688.e1–688.e13. 3 indexed citations
2.
Suzuki, Kazuhito, M. Kawashima, Hiroki Yokoyama, et al.. (2023). Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis. International Journal of Hematology. 119(1). 39–49. 1 indexed citations
3.
Suzuki, Kazuhito, Kaichi Nishiwaki, & Shingo Yano. (2021). Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity. Cancers. 13(19). 4867–4867. 11 indexed citations
4.
Suzuki, Kazuhito, et al.. (2021). Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis. International Journal of Hematology. 114(5). 599–607. 2 indexed citations
5.
Nishiwaki, Kaichi, et al.. (2021). Acute Compartment Syndrome of the Upper Extremity in Acquired Hemophilia A. JBJS Case Connector. 11(3). 1 indexed citations
6.
Suzuki, Kazuhito, Kaichi Nishiwaki, & Shingo Yano. (2021). Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma. Cancers. 13(2). 215–215. 20 indexed citations
7.
Suzuki, Kazuhito, et al.. (2020). Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide. Cancer Medicine. 9(5). 1694–1702. 1 indexed citations
8.
9.
Sakuta, Kenichi, et al.. (2020). Acute myeloid leukemia diagnosed by dysphagia due to bilateral vagus nerve palsy: a case report. Rinsho Shinkeigaku. 60(7). 504–507. 1 indexed citations
10.
11.
Nakaseko, Chiaki, Kaichi Nishiwaki, Hitoshi Ogasawara, et al.. (2018). Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. International Journal of Hematology. 108(2). 176–183. 4 indexed citations
12.
Takahashi, Naoto, Kaichi Nishiwaki, Chiaki Nakaseko, et al.. (2018). Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 103(11). 1835–1842. 59 indexed citations
13.
Miyasaka, Naoyuki, Osamu Miura, Tatsuya Kawaguchi, et al.. (2016). Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. International Journal of Hematology. 103(6). 703–712. 38 indexed citations
14.
15.
Takahashi, Naoto, Chiaki Nakaseko, Kaichi Nishiwaki, & Hisashi Wakita. (2016). Two-Year Consolidation By Nilotinib Is Associated with Successful Treatment Free Remission in Chronic Myeloid Leukemia with MR4.5: Subgroup Analysis from STAT2 Trial in Japan. Blood. 128(22). 1889–1889. 8 indexed citations
16.
Sano, Koji, et al.. (2015). Reversible posterior leukoencephalopathy syndrome during R-ICE therapy for malignant lymphoma. Annals of Oncology. 26. vii110–vii110.
17.
Kumagai, Takashi, Eri Matsuki, Koiti Inokuchi, et al.. (2013). Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. International Journal of Hematology. 99(1). 41–52. 19 indexed citations
18.
Tanaka, Ruriko, Shinya Kimura, Eishi Ashihara, et al.. (2011). Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Letters. 312(2). 228–234. 15 indexed citations
19.
Takahashi, Satoshi, Yasuo Oshima, Kaichi Nishiwaki, et al.. (1998). Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia. American Journal of Hematology. 57(4). 303–308. 13 indexed citations
20.
Kobayashi, Masayuki, Mayumi Yoshida, Ken Kaito, et al.. (1992). [High-dose cepharanthin therapy of idiopathic thrombocytopenic purpura].. PubMed. 33(3). 405–7. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Léonardo Magro Breakdown of academic impact, for papers by Yoshiko Matsuhashi Breakdown of academic impact, for papers by Péter Reményi Breakdown of academic impact, for papers by C. Costello Breakdown of academic impact, for papers by Monica Soracco Breakdown of academic impact, for papers by Chiara Maria Dellacasa Breakdown of academic impact, for papers by Rainer Krahl Breakdown of academic impact, for papers by AH Elmaagacli Breakdown of academic impact, for papers by Toshiro Kawakita Breakdown of academic impact, for papers by Woo‐Sung Min
Rankless by CCL
2026